Literature DB >> 20582577

Effect of wild type PTEN gene on proliferation and invasion of multiple myeloma.

Suyun Wang1, Zhiyong Cheng, Xiaoyang Yang, Kai Deng, Yan Cao, Hao Chen, Ling Pan.   

Abstract

We explored the effect of the wild type PTEN gene on the proliferation, apoptosis and invasive ability of multiple myeloma (MM) cells from MM patients and RPMI 8226 cells (a human myeloma cell line), and the effect of the PTEN/focal adhesion kinase (FAK)/MMP signaling pathway on the invasion activity of RPMI 8226 cells. The proliferation of RPMI 8226 cells and purified myeloma cells from MM patients were markedly inhibited after these cells were transfected with recombinant adenovirus-PTEN vectors containing green fluorescent protein (Ad-PTEN-GFP). Maximum growth inhibition of RPMI 8226 cells and purified myeloma cells from MM patients by AD-PTEN-GFP was 42.01 and 24.75%, respectively. After transfection with PTEN-siRNA, the proliferation of RPMI 8226 cells was increased significantly compared with NS-siRNA transfected controls. The maximal survival rate was 141.55 +/- 8.34% in PTEN-siRNA transfected RPMI 8226 cells. Apoptosis of RPMI 8226 cells or purified myeloma cells from MM patients in the Ad-PTEN-GFP group was increased significantly when compared with that in the Ad-GFP (adenovirus vectors only expressing green fluorescent protein) group (p < 0.01). The cell cycle of RPMI 8226 cells was arrested at the G2/M phase. Furthermore, the number of cells that migrated through the matrigel and filter from the upper chamber to the lower chamber in the transwell assay in the Ad-GFP group was significantly larger than that in the Ad-PTEN-GFP group (52.65 +/- 7.39 vs. 23.50 +/- 6.12, p < 0.01). In the PTEN-siRNA group, the cell number (79.50 +/- 11.89) was significantly larger than that in the NS-siRNA group (47.17 +/- 7.76, p < 0.01). When RPMI 8226 cells were transfected with Ad-PTEN-GFP or NS-siRNA, the expression level of PTEN mRNA was up-regulated, and the expression levels of FAK, MMP-2 and MMP-9 mRNA were down-regulated significantly compared with that of the Ad-GFP group and the PTEN-siRNA group (p < 0.01, p < 0.05). The protein levels of FAK and p-FAK, MMP-2 and MMP-9 in RPMI 8226 cells which were transfected with Ad-PTEN-GFP decreased significantly, but increased significantly in PTEN-siRNA transfected RPMI 8226 cells (p < 0.01, p<0.05). These results indicated that wild type PTEN, which inhibited FAK, MMP-2, and MMP-9, could suppress the proliferation and invasion ability of multiple myeloma cells. Modulating the expression of PTEN may be a potential strategy for the treatment of multiple myeloma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20582577     DOI: 10.1007/s12185-010-0604-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  39 in total

Review 1.  Signaling through focal adhesion kinase.

Authors:  D D Schlaepfer; C R Hauck; D J Sieg
Journal:  Prog Biophys Mol Biol       Date:  1999       Impact factor: 3.667

2.  Analysis of PTEN deletions and mutations in multiple myeloma.

Authors:  Hong Chang; Xiao Ying Qi; Jaime Claudio; Lihua Zhuang; Bruce Patterson; A Keith Stewart
Journal:  Leuk Res       Date:  2005-08-19       Impact factor: 3.156

3.  PTEN is involved in the signal transduction pathway of contact inhibition in endometrial cells.

Authors:  Kazunori Uegaki; Yasunobu Kanamori; Junzo Kigawa; Wakae Kawaguchi; Ruri Kaneko; Jun Naniwa; Masakuni Takahashi; Muneaki Shimada; Tetsuro Oishi; Hiroaki Itamochi; Naoki Terakawa
Journal:  Cell Tissue Res       Date:  2005-11-08       Impact factor: 5.249

4.  Expression of PTEN in PTEN-deficient multiple myeloma cells abolishes tumor growth in vivo.

Authors:  N L Ge; S Rudikoff
Journal:  Oncogene       Date:  2000-08-24       Impact factor: 9.867

Review 5.  Matrix metalloproteinases in multiple myeloma.

Authors:  T Kelly; M Børset; E Abe; D Gaddy-Kurten; R D Sanderson
Journal:  Leuk Lymphoma       Date:  2000-04

Review 6.  Multiple myeloma.

Authors:  Robert A Kyle; S Vincent Rajkumar
Journal:  Blood       Date:  2008-03-15       Impact factor: 22.113

7.  CD27-triggering on primary plasma cell leukaemia cells has anti-apoptotic effects involving mitogen activated protein kinases.

Authors:  Jeroen E J Guikema; Edo Vellenga; Wayel H Abdulahad; Sjoerd Hovenga; Nicolaas A Bos
Journal:  Br J Haematol       Date:  2004-02       Impact factor: 6.998

8.  Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics.

Authors:  R García-Sanz; A Orfão; M González; M D Tabernero; J Bladé; M J Moro; J Fernández-Calvo; M A Sanz; J A Pérez-Simón; A Rasillo; J F Miguel
Journal:  Blood       Date:  1999-02-01       Impact factor: 22.113

9.  PTEN deficiency is a common defect in juvenile myelomonocytic leukemia.

Authors:  Yunying Lucy Liu; Robert P Castleberry; Peter D Emanuel
Journal:  Leuk Res       Date:  2008-11-17       Impact factor: 3.156

10.  The lipid phosphatase activity of PTEN is critical for stabilizing intercellular junctions and reverting invasiveness.

Authors:  L Kotelevets; J van Hengel; E Bruyneel; M Mareel; F van Roy; E Chastre
Journal:  J Cell Biol       Date:  2001-12-24       Impact factor: 10.539

View more
  6 in total

1.  Suppression of human lung cancer cell proliferation and metastasis in vitro by the transducer of ErbB-2.1 (TOB1).

Authors:  Yang Jiao; Ke-kang Sun; Lin Zhao; Jia-ying Xu; Li-li Wang; Sai-jun Fan
Journal:  Acta Pharmacol Sin       Date:  2011-12-12       Impact factor: 6.150

2.  Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth.

Authors:  Emanuela Leone; Eugenio Morelli; Maria T Di Martino; Nicola Amodio; Umberto Foresta; Annamaria Gullà; Marco Rossi; Antonino Neri; Antonio Giordano; Nikhil C Munshi; Kenneth C Anderson; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Clin Cancer Res       Date:  2013-02-27       Impact factor: 12.531

3.  The Role of PTEN in Tumor Angiogenesis.

Authors:  Stéphane Rodriguez; Uyen Huynh-Do
Journal:  J Oncol       Date:  2011-09-05       Impact factor: 4.375

4.  Overcoming inherent resistance to histone deacetylase inhibitors in multiple myeloma cells by targeting pathways integral to the actin cytoskeleton.

Authors:  S Mithraprabhu; T Khong; A Spencer
Journal:  Cell Death Dis       Date:  2014-03-20       Impact factor: 8.469

5.  Gambogenic Acid Exerts Antitumor Activity in Hypoxic Multiple Myeloma Cells by Regulation of miR-21.

Authors:  Ping Liu; Xue Wu; Lu Dai; Zheng Ge; Chong Gao; Hongming Zhang; Fei Wang; Xiaoping Zhang; Baoan Chen
Journal:  J Cancer       Date:  2017-09-16       Impact factor: 4.207

6.  Nuclear Heparanase Regulates Chromatin Remodeling, Gene Expression and PTEN Tumor Suppressor Function.

Authors:  Rada Amin; Kaushlendra Tripathi; Ralph D Sanderson
Journal:  Cells       Date:  2020-09-06       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.